Dutasteride & Finasteride Interaction

Dutasteride (Avodart) and finasteride (Proscar, Propecia) are both 5-alpha reductase inhibitors used for benign prostatic hyperplasia (BPH). While dutasteride inhibits both type 1 and type 2 5-alpha reductase isoenzymes and finasteride selectively inhibits type 2, their combination represents therapeutic duplication with no established clinical benefit.

The concurrent use of these two drugs is generally considered a prescribing error rather than an intentional therapeutic strategy. It may occur when patients see multiple prescribers or when a medication is switched without proper discontinuation of the prior agent. In the case of finasteride for hair loss (Propecia, 1 mg) and dutasteride for BPH, patients may inadvertently take both if they have separate prescriptions for different indications.

No clinical trials support the combination, and the additive suppression of dihydrotestosterone (DHT) increases the risk of sexual side effects, mood changes, and other adverse effects without proven additional efficacy.

Finasteride selectively inhibits 5-alpha reductase type 2, the predominant isoenzyme in the prostate, reducing serum DHT by approximately 70%. Dutasteride inhibits both type 1 and type 2 isoenzymes, reducing serum DHT by more than 90%. Since dutasteride already achieves near-maximal DHT suppression, adding finasteride provides negligible additional pharmacological effect.

Dutasteride has an exceptionally long half-life (approximately 5 weeks), meaning its effects persist for months after discontinuation. If a patient switches from dutasteride to finasteride (or vice versa) without an adequate washout period, they effectively receive both drugs simultaneously for several weeks.

The clinical significance relates primarily to unnecessary adverse effect exposure rather than a dangerous pharmacological interaction. The adverse effects of 5-alpha reductase inhibitors — including decreased libido, erectile dysfunction, ejaculatory disorders, gynecomastia, and mood changes — are dose/exposure-dependent and may be amplified by the combination.

Post-finasteride syndrome (persistent sexual, neurological, and psychological side effects after discontinuation) has been reported and is an active area of research. Whether combined exposure increases this risk is unknown but theoretically concerning.

Additionally, both drugs lower PSA (prostate-specific antigen) levels. Combined use could suppress PSA more than expected, potentially masking prostate cancer detection on screening tests.

The combination should be avoided. Patients should use one 5-alpha reductase inhibitor or the other, not both. For BPH, dutasteride offers dual isoenzyme inhibition and may be preferred when maximal DHT suppression is desired. Finasteride at the BPH dose (5 mg) provides effective therapy for many patients.

For patients who also want to address androgenetic alopecia, both BPH-dose finasteride and dutasteride have hair-preservation effects, so a separate low-dose finasteride (1 mg) is not needed if the patient is already on either drug for BPH.

If switching between the two drugs, clinicians should be aware of dutasteride's very long half-life (5 weeks). When switching from dutasteride to finasteride, there is a prolonged overlap period. When switching from finasteride to dutasteride, finasteride can generally be discontinued immediately as dutasteride reaches steady state.

PSA levels should be interpreted with the understanding that 5-alpha reductase inhibitors reduce PSA by approximately 50% after 6 months. Any PSA value should be doubled for comparison with normal ranges. Sexual function should be assessed at each visit using standardized questionnaires if available.

Liver function does not typically require monitoring for either drug, as hepatotoxicity is rare. However, both drugs should be used with caution in liver disease, as they are hepatically metabolized.

For BPH, alpha-1 blockers (tamsulosin, silodosin, alfuzosin) provide symptom relief through a different mechanism (smooth muscle relaxation) and can be combined with a single 5-alpha reductase inhibitor per the COMBAT trial protocol. Phosphodiesterase-5 inhibitors (tadalafil 5 mg daily) are approved for BPH symptoms and may also address erectile dysfunction. Minimally invasive procedures (UroLift, Rezum, TURP) are options for patients who prefer to avoid long-term medication.